论文部分内容阅读
A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibito
【作 者】
：
【机 构】
：
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
【出 处】
：
2015年临床肿瘤学新进展学术研讨会
【发表日期】
：
2015年3期
其他文献
Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for bio
会议
First-line randomized phase Ⅱ study of gemcitabine/cisplatin plus apatorsen or placebo in patients w
会议
TROG 03.06 and VCOG PR 01-03: The “timing of androgen deprivation therapy in prostate cancer patient
会议
A phase Ⅱ/Ⅲ, double-blind, randomized trial comparing maintenance lapatinib versus placebo after fir
会议
Phase Ⅲ trials of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachex
会议
Long-term safety of fertility preservation by ovarian stimulation and concurrent aromatase inhibitor
会议
Chemotherapy-related cognitive impairment (CRCI), and neurotransmitter signaling, longevity, and inf
会议
会议